Delving into the intricate interplay between CD47 and the tumor immune microenvironment (TIME) to delineate a comprehensive understanding of tumor immune evasion pathways holds promise for the development of tailored therapeutic interventions and the identification of novel immune targets. The gene discussed is CD47; the disease is neoplasm.